Federal Trade Commission has requested further information on Roche's acquisition bid for Syntex. Roche has extended its May 6 tender offer, which was set to expire June 6, until July 1. "Approximately 96 mil." shares of Syntex stock have been tendered to date based on the latest count, the companies say. Roche needs 15 mil. more shares of Syntex to gain a controlling interest under its May 2 acquisition agreement ("The Pink Sheet" May 9, p. 15)
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth